The Fund seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Solactive China Biotech Index NTR. The Manager intends to adopt a combination of physical and synthetic replication strategy. The Fund will invest 50-100% of its NAV directly in Index Securities; and use synthetic replication strategy as an ancillary strategy by investing up to 50% of its NAV in FDIs, mainly funded total return Swap transaction(s) with one or more Swap Counterparty(ies). The Fund may invest in FDIs for hedging or non-hedging purposes, in order to achieve the investment objective and efficient portfolio management.